Mosaic Biosciences and Uniquity Bio announce strategic collaboration in biologics development. Mosaic Biosciences today announced a strategic collaboration with Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. The collaboration brings together Mosaic's platform-agnostic biologics discovery expertise with Uniquity Bio's scientific rigor and clinical-stage pipeline to advance high-quality biologic candidates with the speed and precision that development programs demand. A science-first partnership. Uniquity Bio is a clinical-stage company backed by Blackstone Life Sciences, advancing therapeutic programs in immunology and inflammation with the standards of a global pharma company and the operational agility of a biotech. Its lead asset, solrikitug, is a highly potent monoclonal antibody targeting TSLP across multiple respiratory and gastrointestinal indications with significant unmet need. The collaboration pairs that clinical-stage ambition with Mosaic's integrated discovery model, spanning in vitro display, single B-cell methods, transgenic animal platforms, and emerging AI-enabled screening approaches, to support programs where biology, not platform availability, drives every decision. "We built Mosaic around the belief that the best discovery strategy is one tailored to the biology, not the platform. Uniquity Bio shares that science-first philosophy, and we're proud to support their mission to bring meaningful new medicines to patients." - Jean-Pierre Wery, CEO, Mosaic Biosciences What the collaboration delivers. The partnership combines Mosaic's deep expertise in biologics discovery and lead optimization with Uniquity Bio's focus on developing medicines for indications with significant unmet need. Together, the two organizations aim to move high-quality biologic candidates forward with the scientific depth and strategic coordination that clinical-stage programs require. "Mosaic brings a level of scientific depth and strategic partnership in support of clinical-stage and discovery programs that goes beyond traditional CRO relationships. Their integrated approach and broad discovery capabilities align well with how we think about advancing our pipeline." - Kiyomi Komori, VP of Translational Medicine, Uniquity Bio

A new canola joint venture. Published Today Mosaic Biosciences and Elicit Plant announced the signing of a joint development agreement to identify and develop a new solution for canola for North America. Uding Elicit Plant's proprietary EliTerra technology platform, the program aims to identify and develop a new solution designed to help canola growers preserve yield potential under water-stress conditions.

Mosaic Biosciences launches SortAI, a wet lab validation service built for ai-designed antibody libraries. Mosaic Biosciences today announced the commercial launch of SortAI, a yeast display-based validation service designed specifically for AI-generated antibody sequence panels. SortAI enables AI drug discovery companies to screen model-derived libraries before committing to full recombinant protein production, returning structured experimental data that feeds directly back into model retraining. The bottleneck AI drug discovery can't ignore. Generative AI platforms are transforming antibody drug design, producing campaigns of hundreds of thousands to millions of computationally designed sequences per cycle. Yet the infrastructure built to validate those sequences was designed around traditional single-candidate drug programs: full recombinant expression on every sequence, one at a time. The result is a compounding problem: slow cycles, wasted production budget, and models that cannot improve until the wet lab catches up. Typical CROs produce and characterize whatever sequence list arrives in their inbox. SortAI filters it first. "Generative models can produce thousands of antibody candidates. Wet labs can validate a fraction of them. SortAI triages AI-generated libraries at scale so your best sequences get tested first and nothing falls through." - Eric Furfine, PhD, Chief Scientific Officer, Mosaic Biosciences One engagement. The full triage picture. SortAI delivers a complete triage picture in a single defined engagement: Binding, affinity, epitope binning, developability, and function together: A complete discovery funnel in a single engagement, with deliverables structured for model retraining rather than drug program documentation. Sequence liability review at intake: Mosaic scientists screen panels for CDR liabilities, aggregation motifs, poor expression signals, and other flags most AI algorithms don't account for. Bad sequences are removed before they waste wet lab capacity. Yeast-based selection at library scale: Multi-round selection across panels ranging from hundreds to over millions of sequences, with next-generation sequencing (NGS) at each round to track full population dynamics. Negative data returned as a deliverable: Every selection round generates a negative population. SortAI sequences and returns those alongside ranked positive binders - because what didn't bind is half the training signal. Function pulled forward: Candidates that pass binding are immediately pressure-tested through cell-based functional screening, before expensive downstream development work begins. Binding, affinity, epitope binning, developability, and function together: A complete discovery funnel in a single engagement, with deliverables structured for model retraining rather than drug program documentation. Faster cycles. A fraction of the cost. A production-centric competitor workflow covering binding and affinity alone requires approximately 7 weeks and costs significantly more than a full SortAI engagement, which extends through developability profiling and cell-based functional screening. Sequence enrichment for model training is available as early as 6 weeks from project initiation; a full engagement completes in approximately 14 weeks. The yeast display platform underpinning SortAI scales to 10[7] sequence diversity, three orders of magnitude beyond the throughput of production-centric validation workflows, enabling functional triage at the true scale of AI-generated libraries. "AI companies need data that makes the next design cycle better, not just data that's fast. SortAI is built on the principle that quality of signal matters more than speed of throughput, and that the two aren't mutually exclusive." - Tracey Mullen, Chief Strategy Officer, Mosaic Biosciences Built on demonstrated capability. SortAI is backed by Mosaic's team of 50+ scientists, 80% holding advanced degrees and more than 216 completed discovery programs. The yeast display workflow that powers SortAI has already demonstrated results in library-based screening engagements that competing CROs were unable to accommodate. The platform was first introduced publicly at PEGS Boston 2026 and is now available as a defined commercial service. Detailed pricing and scope information is available upon request under NDA. About Mosaic Biosciences. Mosaic Biosciences is a biologics discovery company specializing in antibody and protein engineering, with expertise spanning transgenic mouse platforms, display technologies, and multispecific antibody formats. Mosaic partners with biotech and pharmaceutical companies to generate high-quality, developable biologics optimized for real-world therapeutic success.